CEL-SCI Announces Multikine Phase 3 Data Accepted For Publication In Oral Oncology, Citing 73% Five-Year Survival vs. 45% For Standard Of Care In Low PD-L1 Head And Neck Cancer
Share
Why It Matters
A medicine company showed their new cancer treatment helped more patients survive five years compared to the usual treatment. When you see a company announce strong results like this, it suggests their medicine might be ready to help real patients soon, which is encouraging news to watch.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.